BioCryst Pharmaceuticals, Inc.'s (BCRX) shares tanked more than 50% on May 21, 2019, after the company announced that it had met primary endpoints in the phase 3 trial of lead candidate BCX7353, a compound designed to be a once-daily orally administered capsule to prevent hereditary angioedema ((HAE)) attacks by inhibiting plasma kallikrein. Investors panicked as the overall efficacy result at 44% was less than the reported 87% of the market leader, and approved drug, in the same indication and mechanism of action ((MOA)), Takhzyro from Takeda (TKPHF).
However, the market fails